請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71977
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 孔繁璐(Fan-Lu Kung) | |
dc.contributor.author | Min-Ji Chen | en |
dc.contributor.author | 陳敏吉 | zh_TW |
dc.date.accessioned | 2021-06-17T06:17:28Z | - |
dc.date.available | 2023-08-30 | |
dc.date.copyright | 2018-08-30 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-20 | |
dc.identifier.citation | 1. Tanaka, M., Tanaka, M., Nakata, Y., Mori, T., Okamura, Y., Miyasaka, H., and Takeyama, H., Development of a cell surface display system in a magnetotactic bacterium, 'Magnetospirillum magneticum' AMB-1. Appl Environ Microbiol, 2008. 74(11): p. 3342-8.
2. Rothe, A., R.J. Hosse, and B.E. Power, In vitro display technologies reveal novel biopharmaceutics. FASEB J, 2006. 20(10): p. 1599-610. 3. Reverdatto, S., D.S. Burz, and Shekhtman, A., Peptide Aptamers: Development and Applications. Curr Top Med Chem, 2015. 15(12): p. 1082–1101. 4. Fosgerau, K. and Hoffmann T., Peptide therapeutics: current status and future directions. Drug Discov Today, 2015. 20(1): p. 122-8. 5. Salema, V. and L.A. Fernandez, Escherichia coli surface display for the selection of nanobodies. Microb Biotechnol, 2017. 10(6): p. 1468-1484. 6. Bosma, T., Kuipers, A., Bulten, E., Vries, L.D., Rink, R., and Moll, G. N, Bacterial display and screening of posttranslationally thioether-stabilized peptides. Appl Environ Microbiol, 2011. 77(19): p. 6794-801. 7. Tafakori, V., Torktaz, I., Doostmohammadi, M., and Ahmadian, G., Microbial cell surface display; its medical and environmental applications. Iranian J Biotechnol, 2012. 10(4): p. 231-9. 8. Kenrick, S.A. and P.S. Daugherty, Bacterial display enables efficient and quantitative peptide affinity maturation. Protein Eng Des Sel, 2010. 23(1): p. 9-17. 9. J.A. Getz, T.D. Schoep, and P.S. Daugherty, Peptide Discovery Using Bacterial Display and Flow Cytometry. Methods Enzymol, 2012. 503(4): p. 75-97. 10. P.S. Daugherty, Protein engineering with bacterial display. Curr Opin Struct Biol, 2007. 17(4): p. 474-80. 11. Vogt, J., and G.E. Schulz, The structure of the outer membrane protein OmpX from Escherichia coli reveals possible mechanisms of virulence. Cell, 1999. 7(10): p. 1301-9. 12. J.J. Rice, and P.S. Daugherty, Directed evolution of a biterminal bacterial display scaffold enhances the display of diverse peptides. Protein Eng Des Sel, 2008. 21(7): p. 435-42. 13. Holger, J., Memory loss in Alzheimer's disease. Dialogues Clin Neurosci, 2013. 15(4): p. 445-454. 14. Götz, J., Schild, A., Hoerndli, F., and Pennanen, L., Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci, 2004. 22(7): p. 453-65. 15. Iwata, N., Higuchi, M., and T.C. Saido, Metabolism of amyloid-β peptide and alzheimer's disease. Pharmacol Ther, 2005.108(2): p. 129-148. 16. M.P. Murphy, and LeVine, H., Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis, 2010. 19(1): p. 311-23. 17. Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., and Mahmoudi, J., Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract, 2015. 24(1): p. 1-10. 18. O'Brien R.J., and Wong P.C., Amyloid precursor protein processing and Alzheimer's disease. Ann Rev Neurosci. 2011. 34(1): p. 185-204. 19. Zenaro, E., G. Piacentino, and G. Constantin, The blood-brain barrier in Alzheimer's disease. Neurobiol Dis, 2017. 107: p. 41-56. 20. Spencer, B., Potkar, R., Metcalf, J., Thrin, I., Adame, A., Rockenstein, E., and Masliah, E., Systemic Ceantral Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem, 2016. 291(4): p. 1905-20. 21. J.R. Clarke, L.E.S. NM, C.P. Figueiredo, R.L. Frozza, J.H. Ledo, and Beckman, D., Alzheimer-associated Abeta oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med, 2015. 7(2): p. 190-210. 22. Reitz, C., Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J Alzheimers Dis, 2012. 30(2): p. S127-45. 23. A.L. Heffernan, Chidgey, C., Peng, P., C.L. Masters, B.R. Roberts, A.L. Heffernan, The Neurobiology and Age-Related Prevalence of the epsilon4 Allele of Apolipoprotein E in Alzheimer's Disease Cohorts. J Mol Neurosci, 2016. 60(3): p. 316-324. 24. C.C. Liu, Kanekiyo T., H.X. Xu, and Bu G., Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat Revs Neurol, 2013.9(4): p. 106-118. 25. Kanekiyo, T., Xu H., and Bu G., ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? Neuron, 2014. 81(4): p. 740-54. 26. Y.A. Huang, Zhou B. , Wernig, M., T.C. Südhof, ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion. Cell, 2017. 168(3): p. 427-441 27. D.M. Holtzman, Herz, J., and Bu G., Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med, 2012. 2(3). doi: 10.1101/cshperspect.a006312. 28. Li, J., Kanekiyo, T., Shinohara, M., Zhang, Y., M.J. Ladu, and Xu, H., Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem, 2012. 287(53): p. 44593-601. 29. Leduc, V., Domenger, D., B.L. De, Lalonde, D., Bélangerjasmin, S., Function and comorbidities of apolipoprotein e in Alzheimer's disease. Int J Alzheimers Dis, 2011. 29: p. e974361. doi: 10.4061/2011/974361. 30. Deane, R., Sagare, A., Hamm, K., D.M. Holtzman, B.V. Zlokovic, apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest, 2008. 118(12): p. 4002-4013. 31. E.J. Lee and J.H. Park, Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases. Genomics Inform, 2013. 11(4): p. 224-9. 32. Bongarzone, S., Savickas, V., Luzi, F., and A.D. Gee., Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem, 2017. 60(17): p. 7213-32. 33. Y.K. Chuah, Basir, R., Talib, H., T.H. Tie, Nordin, N., Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam, 2013. doi:10.1155/2013/403460. 34. H.H. Jarosz-Griffiths, Noble, E., J.V. Rushworth, and N.M. Hooper, Amyloid-beta Receptors: The Good, the Bad, and the Prion Protein. J Biol Chem, 2016. 291(7): p. 3174-83. 35. Christiane, O., Kathleen, J., Elisa, H., N.S. Anne, Tilman, G., and Andreas, Role of advanced glycation end products in cellular signaling. Redox Biol, 2014.2: p. 411-29. 36. Guglielmotto, M., Aragno, M., Tamagno, E., Vercellinatto, I., Visentin, S., and Medana, C., AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging, 2012. 33(1): p. 196.e13-27. 37. W.Y. Wang, M.S. Tan, J.T. Yu, and Tan, L., Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med, 2015. 3(10): p. 136-147. 38. Chami, L., and Checler F., BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer's disease. Mol Neurodegener, 2012. 7(1) : p. 52-67. 39. Arancio, O., H.P. Zhang, Chen, X., Lin, C., Trinchese, F., and Puzzo, D., Arancio1 RAGE potentiates Ab-induced perturbation of neuronal function in transgenic mice, EMBO J, 2004.23 : p. 4096–4105. 40. Berghammer, H., and Auer, B., 'easypreps': fast and easy plasmid minipreparation for analysis of recombinant clones in e. coli, Biotech, 1993.14(4): p. 524-528. 41. M.F. Tavazoie, Pollack, I., Tanqueco, R., B.N. Ostendorf, B.S. Reis, and F.C. Gonsalves, LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell, 2018. 172(4): p. 825-840e18. 42. T.J. Santangelo, and Artsimovitch I., Termination and antitermination: RNA polymerase runs a stop sign. Nat Rev Microbiol, 2011. 9(5): p. 319-29. 43. Costa, S., Almeida, A., Castro, A., and Domingues, L., Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system. Front Microbiol, 2014. 5(63). doi: 10.3389/fmicb.2014.00063. 44. Kurepa, J., J.M. Walker, Smalle, J., M.M. Gosink, S.J. Davis, and T.L. Durham, The small ubiquitin-like modifier (SUMO) protein modification system in Arabidopsis. Accumulation of SUMO1 and -2 conjugates is increased by stress. J Biol Chem, 2003. 278(9): p. 6862-72. 45. Reuten, R., Nikodemus, D., M.B. Oliveira, T.R. Patel, Brachvogel, B., and Breloy, I., Maltose-Binding Protein (MBP), a SecretionEnhancing Tag for Mammalian Protein Expression Systems, PLoS ONE, 2016. 11(3): p. e0152386. doi: 10.1371/journal.pone.0152386. eCollection 2016. 46. Schneider, C., R.A. Newman, D.R. Sutherland, Asser, U., and M.F. Greaves, A One-step Purification of Membrane Proteins Using a High Efficiency Immunomatrix, J Biol Chem, 1982. 257: p. 10766-10769. 47. Spiga, O., Bernini, A., Scarselli, M., Ciutti, A., Bracci, L., and Lozzi, L., Peptide-protein interactions studied by surface plasmon and nuclear magnetic resonances, Febs Lett, 2002.511: p. 33-35. 48. J.A. Getz, T.D. Schoep, and P.S. Daugherty, Peptide Discovery Using Bacterial Display and Flow Cytometry, Methods Enzymol, 2012.503: p. 75-97. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71977 | - |
dc.description.abstract | 阿茲海默症是一種起病因尚不明確的不可逆、進行性神經系統退行性疾病,特徵主要為澱粉樣蛋白斑塊(amyloid plaques)及神經原纖維纏(neurofibrillary tangles)的形成、腦中神經細胞間連結的減少和神經細胞的凋亡。絕大多數患者的阿茲海默症屬於晚發型,發生在60歲以後,雖然晚發型阿茲海默症至今還未發現特定的致病基因,但研究表明一些危險因子(risk factor)會增加病情惡化的風險,比如E型載脂肪蛋白 (APOE, Apolipoprotein E)、晚期糖化終產物受體(RAGE,receptor of product of advanced glycation end products)。為了得到能與APOE、RAGE產生相互作用的肽 (peptide),並以此肽為基礎進行結構設計,得到可以影響APOE、RAGE作用的肽類藥物。在本論文中利用細菌表面展示技術進行篩選。在篩選之前,需先得到APOE和RAGE蛋白。首先建構包含glutathione S-transferase (GST)-及APOE或RAGE基因之質体,轉化至大腸桿菌中表現出GST-APOE和GST-RAGE融合蛋白,並試圖採用親合性和分子篩層析法純化。但由於APOE表達量受限,無法得到過表達的蛋白進行後續純化;而RAGE又因是一個跨膜蛋白,並且膜外疏水性側鏈聚集纏繞導致形成沒有活性的包涵體(inclusion body),雖嘗試藉由將包涵體變性、再以透析復性等方法處理,但在復性過程中蛋白質構型發生改變,無法得到可直接應用於篩選之純化蛋白,因此利用抗原抗體特異性作用幫助篩選進行。
為了高效率篩選互作多肽,利用細菌表面展示隨機肽庫結合流式細胞分選技術。細菌細胞表面展示技術是通過重組 DNA 技術,將外源功能蛋白表達並定位於特定細菌細胞的表面。本論文藉由在細菌表面展示隨機15肽庫,篩選出能夠與RAGE產生相互作用的肽,並經dot-blot初步鑒定結合能力,並測序分析肽序列,為下一步研究提供基礎。 | zh_TW |
dc.description.abstract | Alzheimer's disease is an irreversible and progressive neurodegenerative disorder with unclear causes. It is characterized by the formation of amyloid plaques and neurofibrillary tangles, decrease of interneuronal connections and apoptosis of nerve cells in the brain. The vast majority of Alzheimer's disease belongs to late-onset and occurs after the age of 60. Although late-onset Alzheimer's disease has not yet been found to have a specific causative gene, studies have shown that some risk factors may increase the risk of disease progression, such as APOE (apolipoprotein E) and RAGE (receptor of product of advanced glycation end products). To identify peptides that bind to APOE or RAGE and design peptide drugs which can modulate the disease-associated activities of these risk factors, it is desirable to obtain pure APOE and RAGE first. Plasmid constructs encoding fusion proteins of glutathion S-transferase and APOE/RAGE were used to overexpress GST-APOE and GST-RAGE fusion protein in Escherichia coli, which were later purified using affinity chromatography and size exclusion chromatography. However, the expression level of GST-APOE was too low to be purified; RAGE, on the other hand, formed inclusion bodies, probably due to its being a transmembrane protein with hydrophobic side chains aggregated and entangled out of the membrane. Although we tried to denature/renature inclusion bodies to obtain functioning RAGE, as protein conformation seemed to be changed during the renaturation process, the attempt to obtain purified protein used directly for screening purpose was unsuccessful. GST-protein-peptide interaction was therefore monitored by indirect antigen-antibody specific interaction instead.
In order to screen for interacting peptides efficiently, a bacterial surface display random peptide library combined with flow cytometric sorting technology was applied. Bacterial cell surface display technology uses recombinant DNA technology to express and localize foreign functional proteins on the surface of specific bacterial cells. In this dissertation, a random 15 peptide library was designed to screen out RAGE-interacting peptides, whose binding ability were preliminarily verified by dot-blot analysis. The identities of the candidate RAGE-interacting peptides were determined by sequencing analysis and subject to further studies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:17:28Z (GMT). No. of bitstreams: 1 ntu-107-R04423028-1.pdf: 1959107 bytes, checksum: 114d68c2d46af055d282fc4230464cf4 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員審定書.. ... … … … … … … … … … … … … … … … ... ... ……… …i
致謝... … ... … … … … … … … … … … … … … … … … … … … … …… … ii Contents ..... … ... … … … … … … … … … … … … … … … … … … … … …iii 中文摘要.… ... … ... … … … … … … … … … … … … … … … … … … … …1 English Abstract... … … … … … … … … … … … … … … … … … … … … ...3 Abbreviations .… … … … … … … … … … … … … … … … … … … … … …5 Introduction… … … … … … … … … … … … … … … … … … … … … … …6 Objective.. … … … … … … … … … … … … … … … … … … … … … … …11 Materials and Methods.… … … … … … … … … … … … … … … … … … …12 Results..… … … … … … … … … … … … … … … … … … … … … … … …28 Discussion... .… … … … … … … … … … … … … … … … … … … … … … 38 Figures .. … … … … … … … … … … … … … … … … … … … … … … … ..41 Tables.. … … … … … … … … … … … … … … … … … … … … … … … …61 References. … … … … … … … … … … … … … … … … … … … … … … ...65 | |
dc.title | 應用細菌表面展示技術篩選APOE和RAGE的互作肽 | zh_TW |
dc.title | Screening for APOE- or RAGE-interacting Peptides using Bacterial Display Technique | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 許麗卿,忻凌偉 | |
dc.subject.keyword | APOE,RAGE,細菌表面展示技術,隨機?庫,流式細胞術, | zh_TW |
dc.subject.keyword | APOE,RAGE,bacterial surface display,random peptide library,flow cytometry, | en |
dc.relation.page | 71 | |
dc.identifier.doi | 10.6342/NTU201804026 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 1.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。